346 related articles for article (PubMed ID: 24436421)
1. Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas.
Schramek D; Sendoel A; Segal JP; Beronja S; Heller E; Oristian D; Reva B; Fuchs E
Science; 2014 Jan; 343(6168):309-13. PubMed ID: 24436421
[TBL] [Abstract][Full Text] [Related]
2. Nonmuscle myosin IIA is associated with poor prognosis of esophageal squamous cancer.
Xia ZK; Yuan YC; Yin N; Yin BL; Tan ZP; Hu YR
Dis Esophagus; 2012 Jul; 25(5):427-36. PubMed ID: 21951916
[TBL] [Abstract][Full Text] [Related]
3. MYH9 regulates p53 stability and is a tumor suppressor in SCC.
Cancer Discov; 2014 Mar; 4(3):OF22. PubMed ID: 24596217
[TBL] [Abstract][Full Text] [Related]
4. The tumor suppressor capability of p53 is dependent on non-muscle myosin IIA function in head and neck cancer.
Coaxum SD; Tiedeken J; Garrett-Mayer E; Myers J; Rosenzweig SA; Neskey DM
Oncotarget; 2017 Apr; 8(14):22991-23007. PubMed ID: 28160562
[TBL] [Abstract][Full Text] [Related]
5. Conditional deletion of nonmuscle myosin II-A in mouse tongue epithelium results in squamous cell carcinoma.
Conti MA; Saleh AD; Brinster LR; Cheng H; Chen Z; Cornelius S; Liu C; Ma X; Van Waes C; Adelstein RS
Sci Rep; 2015 Sep; 5():14068. PubMed ID: 26369831
[TBL] [Abstract][Full Text] [Related]
6. The abnormal proplatelet formation in MYH9-related macrothrombocytopenia results from an increased actomyosin contractility and is rescued by myosin IIA inhibition.
Chen Y; Boukour S; Milloud R; Favier R; Saposnik B; Schlegel N; Nurden A; Raslova H; Vainchenker W; Balland M; Nurden P; Debili N
J Thromb Haemost; 2013 Dec; 11(12):2163-75. PubMed ID: 24165359
[TBL] [Abstract][Full Text] [Related]
7. Myosin Heavy Chain 9: Oncogene or Tumor Suppressor Gene?
Wang Y; Liu S; Zhang Y; Yang J
Med Sci Monit; 2019 Jan; 25():888-892. PubMed ID: 30739906
[TBL] [Abstract][Full Text] [Related]
8. Podocyte-specific deletion of Myh9 encoding nonmuscle myosin heavy chain 2A predisposes mice to glomerulopathy.
Johnstone DB; Zhang J; George B; Léon C; Gachet C; Wong H; Parekh R; Holzman LB
Mol Cell Biol; 2011 May; 31(10):2162-70. PubMed ID: 21402784
[TBL] [Abstract][Full Text] [Related]
9. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes.
Heath KE; Campos-Barros A; Toren A; Rozenfeld-Granot G; Carlsson LE; Savige J; Denison JC; Gregory MC; White JG; Barker DF; Greinacher A; Epstein CJ; Glucksman MJ; Martignetti JA
Am J Hum Genet; 2001 Nov; 69(5):1033-45. PubMed ID: 11590545
[TBL] [Abstract][Full Text] [Related]
10. Of mice and men: Relevance of cellular and molecular characterizations of myosin IIA to MYH9-related human disease.
Even-Ram S; Yamada KM
Cell Adh Migr; 2007; 1(3):152-5. PubMed ID: 19262128
[TBL] [Abstract][Full Text] [Related]
11. Megakaryocyte migration defects due to nonmuscle myosin IIA mutations underlie thrombocytopenia in MYH9-related disease.
Pal K; Nowak R; Billington N; Liu R; Ghosh A; Sellers JR; Fowler VM
Blood; 2020 May; 135(21):1887-1898. PubMed ID: 32315395
[TBL] [Abstract][Full Text] [Related]
12. Advances in the understanding of MYH9 disorders.
Kunishima S; Saito H
Curr Opin Hematol; 2010 Sep; 17(5):405-10. PubMed ID: 20601875
[TBL] [Abstract][Full Text] [Related]
13. [Autosomal dominant macrothrombocytopenia with leukocyte inclusion bodies and MYH9 disorders].
Kunishima S
Rinsho Byori; 2009 Apr; 57(4):365-70. PubMed ID: 19489439
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma.
DeYoung MP; Johannessen CM; Leong CO; Faquin W; Rocco JW; Ellisen LW
Cancer Res; 2006 Oct; 66(19):9362-8. PubMed ID: 17018588
[TBL] [Abstract][Full Text] [Related]
15. Nonmuscle Myosin Heavy Chain IIA Mutation Predicts Severity and Progression of Sensorineural Hearing Loss in Patients With MYH9-Related Disease.
Verver EJ; Topsakal V; Kunst HP; Huygen PL; Heller PG; Pujol-Moix N; Savoia A; Benazzo M; Fierro T; Grolman W; Gresele P; Pecci A
Ear Hear; 2016; 37(1):112-20. PubMed ID: 26226608
[TBL] [Abstract][Full Text] [Related]
16. G to T transversion at the first nucleotide of exon 26 of the MYH9 gene results in a novel missense mutation and abnormal splicing in platelets: comment on "A G to C transversion at the last nucleotide of exon 25 of the MYH9 gene results in a missense mutation rather than in a splicing defecton" by Vettore et al.
Kunishima S; Tomii T; Kudo K; Saito H
Eur J Med Genet; 2012 Dec; 55(12):763-5. PubMed ID: 22982478
[No Abstract] [Full Text] [Related]
17. Non-muscle myosin heavy chain IIA and IIB interact and co-localize in living cells: relevance for MYH9-related disease.
Marini M; Bruschi M; Pecci A; Romagnoli R; Musante L; Candiano G; Ghiggeri GM; Balduini C; Seri M; Ravazzolo R
Int J Mol Med; 2006 May; 17(5):729-36. PubMed ID: 16596254
[TBL] [Abstract][Full Text] [Related]
18. The collagen receptor DDR1 regulates cell spreading and motility by associating with myosin IIA.
Huang Y; Arora P; McCulloch CA; Vogel WF
J Cell Sci; 2009 May; 122(Pt 10):1637-46. PubMed ID: 19401332
[TBL] [Abstract][Full Text] [Related]
19. The irreversibility of platelet aggregation is regulated by myosin IIA, but is not compromised in MYH9-related disease.
Catricalà S; Guidetti GF; Canobbio I; Pecci A; Balduini CL; Balduini C; Torti M
Thromb Res; 2011 Feb; 127(2):171-3. PubMed ID: 20828798
[No Abstract] [Full Text] [Related]
20. Myosin IIA is critical for organelle distribution and F-actin organization in megakaryocytes and platelets.
Pertuy F; Eckly A; Weber J; Proamer F; Rinckel JY; Lanza F; Gachet C; Léon C
Blood; 2014 Feb; 123(8):1261-9. PubMed ID: 24243973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
